- Assistant Professor, CWRU School of Medicine
Mohamed Elkasaby, MD, is a neurologist at University Hospitals Cleveland Medical Center. He is trained in movement disorders and cognitive neurology. His special interests include Parkinson’s disease, dementia, tremor, dystonia, botulinum toxin injections and deep brain stimulation.
Dr. Elkasaby earned his medical degree from Ain Shams University in Egypt, where he completed his internship. He completed his neurology residency in Germany and worked as a neurology specialist there. He is board certified in neurology in Germany. He is a fellow of the European Board of Neurology.
He completed two years of clinical fellowship in movement disorders and neuromodulation at University Hospitals, and a clinical fellowship in behavioral neurology and neuropsychiatry at University Hospitals.
Dr. Elkasaby has written several peer-reviewed articles, abstracts and book chapters focusing on movement disorders and dementia. Dr. Elkasaby has also served as a reviewer for prominent medical journals focusing on movement disorders and dementia. He is a Steering Committee Member at the Alzheimer’s Disease Cooperative Study (ADCS), which is a part of the National Institute on Aging (NIA) Division of Neuroscience’s effort to facilitate the discovery, development and testing of new drugs for the treatment of Alzheimer’s Disease, and is a part of Alzheimer’s Disease Prevention Initiative as well. Dr. Elkasaby is a member of the American Academy of Neurology, the European Academy of Neurology, the Movement Disorder Society and the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment.
- Botulinum Toxin Injections
- Deep Brain Stimulation (DBS)
- Parkinson's Disease
English, German, Arabic
Fellowship | Behavioral Neurology and Neuropsychiatry
Behavioral Neurology and Neuropsychiatry - UH Cleveland Medical Center (2021 - 2022)
Fellowship | Movement Disorders
Movement Disorders - UH Cleveland Medical Center (2019 - 2021)
Residency | Neurology
Neurology - Helios Clinic Bonn – Rhein-Sieg Hospital (2012 - 2018)
Ain Shams University Faculty Of Medicine (2009)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Mohamed Elkasaby did not disclose any Outside Relationships with Industry.